Fisetin for Protein Folding Support
Fisetin is an early-stage senolytic candidate with no completed human outcome trials.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- Intermittent high-dose protocols used in trials
- Expected timeframe
- Unknown
Protocol
- form
- Not applicable
- duration
- Not applicable
- co factor
- Evidence is insufficient. Fisetin induces autophagy and has been reported to reduce aggregation of misfolded proteins - amyloid-beta, tau and alpha-synuclein - in cell culture and animal models, and to modulate heat shock response pathways. Every one of those findings is preclinical. No human study has measured protein aggregation, chaperone activity or any proteostasis marker after fisetin, and there is no accepted clinical assay for doing so. This is a mechanistic hypothesis presented as an outcome.
- titration
- Not applicable
- starting dose
- Not applicable
Evidence
What the studies say
No studies are yet linked to both Fisetin and Protein Folding Support.
Safety
Caveats
Purely investigational. Doses used in research greatly exceed dietary intake.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.